Zacks Research Has Pessimistic Outlook of MTD Q2 Earnings

Mettler-Toledo International Inc. (NYSE:MTD) – Stock analysts at Zacks Research reduced their Q2 2025 earnings per share estimates for Mettler-Toledo International in a report issued on Thursday, May 22nd. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $9.55 per share for the quarter, down from their prior estimate of $10.18. The consensus estimate for Mettler-Toledo International’s current full-year earnings is $42.71 per share. Zacks Research also issued estimates for Mettler-Toledo International’s Q4 2026 earnings at $14.08 EPS, FY2026 earnings at $45.83 EPS, Q1 2027 earnings at $10.55 EPS and FY2027 earnings at $54.17 EPS.

Mettler-Toledo International (NYSE:MTD) last released its earnings results on Thursday, May 1st. The medical instruments supplier reported $8.19 EPS for the quarter, beating the consensus estimate of $7.90 by $0.29. The firm had revenue of $883.74 million for the quarter, compared to analysts’ expectations of $876.61 million. Mettler-Toledo International had a negative return on equity of 591.54% and a net margin of 22.29%. The business’s quarterly revenue was down 4.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $8.89 EPS.

MTD has been the topic of several other reports. Citigroup raised Mettler-Toledo International from a “neutral” rating to a “buy” rating and set a $1,400.00 target price on the stock in a report on Monday, April 7th. Jefferies Financial Group raised Mettler-Toledo International from an “underperform” rating to a “hold” rating and cut their price target for the company from $1,200.00 to $1,110.00 in a research note on Monday, May 5th. Evercore ISI raised their price objective on Mettler-Toledo International from $1,450.00 to $1,475.00 and gave the stock an “outperform” rating in a research report on Monday, February 10th. UBS Group upgraded Mettler-Toledo International from a “neutral” rating to a “buy” rating and lowered their target price for the stock from $1,530.00 to $1,350.00 in a report on Tuesday, May 20th. Finally, Robert W. Baird lowered their target price on Mettler-Toledo International from $1,369.00 to $1,034.00 and set a “neutral” rating for the company in a report on Tuesday, April 22nd. Seven investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $1,302.11.

Mettler-Toledo International Trading Down 1.8%

MTD stock opened at $1,115.43 on Monday. The business’s 50 day simple moving average is $1,099.07 and its 200 day simple moving average is $1,209.39. Mettler-Toledo International has a 1-year low of $946.69 and a 1-year high of $1,546.93. The firm has a market capitalization of $23.18 billion, a PE ratio of 27.52, a PEG ratio of 3.30 and a beta of 1.40.

Institutional Investors Weigh In On Mettler-Toledo International

Several institutional investors have recently bought and sold shares of MTD. Vanguard Group Inc. raised its position in Mettler-Toledo International by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 2,543,365 shares of the medical instruments supplier’s stock valued at $3,003,485,000 after purchasing an additional 30,535 shares during the last quarter. Alliancebernstein L.P. boosted its stake in Mettler-Toledo International by 21.6% during the 1st quarter. Alliancebernstein L.P. now owns 709,328 shares of the medical instruments supplier’s stock valued at $837,653,000 after purchasing an additional 126,147 shares during the last quarter. Geode Capital Management LLC boosted its stake in Mettler-Toledo International by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 558,471 shares of the medical instruments supplier’s stock valued at $682,340,000 after purchasing an additional 11,032 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Mettler-Toledo International by 5.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 481,011 shares of the medical instruments supplier’s stock worth $568,032,000 after buying an additional 25,272 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its stake in shares of Mettler-Toledo International by 11.9% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 406,189 shares of the medical instruments supplier’s stock worth $479,673,000 after buying an additional 43,082 shares during the last quarter. 95.07% of the stock is currently owned by hedge funds and other institutional investors.

About Mettler-Toledo International

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company’s laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments.